Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyte approach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners.
Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug development, and company formation. Our name is inspired by the focal point of our science, the mitochondrion, whose highly folded inner membrane is one of many fascinating features that make it unlike any other organelle in the body.
Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease in ways that were not previously possible. To produce an extended portfolio of medications, the company is developing an innovative platform at the confluence of RNA technology, delivery techniques, data analytics, and automation.
Vizgen, Inc. is a biotechnology company focused on developing advanced spatially resolved transcriptomic profiling tools to enhance understanding of biological systems related to human health and disease. Its flagship technology, MERFISH, is a patented multiplexed single-molecule imaging method that allows for the simultaneous measurement of RNA species' copy number and spatial distribution within individual cells. This innovative approach facilitates single-cell gene expression profiling in intact tissue slices, providing valuable insights into various diseases and biological processes. The applications of Vizgen's technology span several fields, including oncology, immunology, neuroscience, infectious diseases, developmental biology, and regenerative medicine. Founded in 2019 and headquartered in Cambridge, Massachusetts, Vizgen aims to support tissue-scale research and development, contributing to the discovery and mapping of diverse cell types and states across multiple tissues and organisms.
Remix Therapeutics Inc. engages in the biotech research and development business. It discovers and develops various novel therapeutic RNA processing modulators to target various undruggable disease drivers. The company also offers biology platform to identify and prioritize targets with therapeutically-tractable intervention points in RNA processing. Its REMseq platform validates targets and chemical matter discovery and optimization. The company was founded in 2018 and is based in Cambridge, Massachusetts.
Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells within the immune system. The company aims to address significant limitations associated with existing cell and gene therapies, such as the challenges of administering multiple doses, unpredictable patient reactions, and the necessity of potentially harmful chemotherapy regimens prior to treatment. Be Biopharma's approach allows for the creation of durable therapies that can be re-administered without toxic conditioning, making these treatments suitable for a range of diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020, Be Biopharma is headquartered in Cambridge, Massachusetts.
Proof Diagnostics develops CRISPR‑based COVID‑19 molecular tests to help communities take control of their health.
hC Bioscience is an innovator and pioneer of protein editing using context agnostic engineered tRNA. Their First in Class approach for protein editing advances beyond genome editing to direct modification of the proteome.
ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, ROME Therapeutics is pioneering the exploration of the repeatome, which consists of extensive regions of genetic material previously considered "junk DNA." The company has identified several drug targets and is actively advancing multiple discovery programs. To facilitate its research, ROME has assembled a team of experts across various disciplines, including oncology, immunology, virology, and machine learning, to harness this uncharted area of biology for therapeutic advancements.
ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases.
Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions. The company was founded in 2021 and is headquartered in Stamford, CT.
Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and will eventually be valuable for clinical diagnostic use.
It was founded in 2015 and headquartered in Cambridge, Massachusetts.
Vizgen, Inc. is a biotechnology company focused on developing advanced spatially resolved transcriptomic profiling tools to enhance understanding of biological systems related to human health and disease. Its flagship technology, MERFISH, is a patented multiplexed single-molecule imaging method that allows for the simultaneous measurement of RNA species' copy number and spatial distribution within individual cells. This innovative approach facilitates single-cell gene expression profiling in intact tissue slices, providing valuable insights into various diseases and biological processes. The applications of Vizgen's technology span several fields, including oncology, immunology, neuroscience, infectious diseases, developmental biology, and regenerative medicine. Founded in 2019 and headquartered in Cambridge, Massachusetts, Vizgen aims to support tissue-scale research and development, contributing to the discovery and mapping of diverse cell types and states across multiple tissues and organisms.
ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases.
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.
The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.
Remix Therapeutics Inc. engages in the biotech research and development business. It discovers and develops various novel therapeutic RNA processing modulators to target various undruggable disease drivers. The company also offers biology platform to identify and prioritize targets with therapeutically-tractable intervention points in RNA processing. Its REMseq platform validates targets and chemical matter discovery and optimization. The company was founded in 2018 and is based in Cambridge, Massachusetts.
Walden Biosciences, Inc, a biotechnology company, develops medicines for individuals living with kidney disease. It targets suPAR, an inflammatory biomarker that connects the kidney to the innate immune system; and Dynamin, a complex enzyme that rebuilds podocytes and the base structure of the kidney. The company was incorporated in 2013 and is based in Cambridge, Massachusetts.
Dewpoint Therapeutics, Inc. is a biotech company focused on researching biomolecular condensates and their role in cellular function. Established in 2018 and based in Boston, Massachusetts, the company aims to develop innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunology, cardiovascular conditions, women’s health, and virology. Dewpoint Therapeutics utilizes a novel drug platform that specifically targets biomolecular condensates to advance its therapeutic solutions.
Glympse Bio, Inc. is focused on developing modular nanoparticle sensors for diagnostics in fibrosis, cancer, immunology, and infectious diseases, as well as for monitoring drug response. The company utilizes engineered diagnostic agents that assess disease states within the body and convey this information to urine for analysis. Its flagship product, Glympse Inside, serves as a pan-disease engine intended to enhance disease monitoring and treatment response. Founded in 2015 and based in Cambridge, Massachusetts, Glympse Bio's innovative platform technology originated at MIT and is backed by a team of experts in nanomedicine and biomedical engineering.
Verve Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to reduce the risk of coronary artery disease, a leading cause of death globally. Founded in 2018 and headquartered in Cambridge, Massachusetts, with a research facility in Philadelphia, the company leverages human genetic analysis and gene-editing technologies to create treatments that offer lifelong protection from this condition. Verve has established strategic alliances, including collaborations with Beam Therapeutics to advance delivery technologies targeting cardiovascular issues and with Verily for developing gene editing delivery vehicles. Formerly known as Endcadia, Verve Therapeutics rebranded in September 2019 to reflect its commitment to addressing heart disease through advanced genetic solutions.
ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, ROME Therapeutics is pioneering the exploration of the repeatome, which consists of extensive regions of genetic material previously considered "junk DNA." The company has identified several drug targets and is actively advancing multiple discovery programs. To facilitate its research, ROME has assembled a team of experts across various disciplines, including oncology, immunology, virology, and machine learning, to harness this uncharted area of biology for therapeutic advancements.
Vizgen, Inc. is a biotechnology company focused on developing advanced spatially resolved transcriptomic profiling tools to enhance understanding of biological systems related to human health and disease. Its flagship technology, MERFISH, is a patented multiplexed single-molecule imaging method that allows for the simultaneous measurement of RNA species' copy number and spatial distribution within individual cells. This innovative approach facilitates single-cell gene expression profiling in intact tissue slices, providing valuable insights into various diseases and biological processes. The applications of Vizgen's technology span several fields, including oncology, immunology, neuroscience, infectious diseases, developmental biology, and regenerative medicine. Founded in 2019 and headquartered in Cambridge, Massachusetts, Vizgen aims to support tissue-scale research and development, contributing to the discovery and mapping of diverse cell types and states across multiple tissues and organisms.
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.
The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.
Voxel8 Inc. designs and manufactures electronic devices. It offers desktop 3D printers that are used to print thermoplastics or UV resins. The company also provides Project Wire, a cloud software tool that is used for designing 3D printable electronic devices that can be rapidly fabricated using the Voxel8 3D printer. Voxel8 Inc. was incorporated in 2013 and is based in Somerville, Massachusetts.
Voxel8 Inc. designs and manufactures electronic devices. It offers desktop 3D printers that are used to print thermoplastics or UV resins. The company also provides Project Wire, a cloud software tool that is used for designing 3D printable electronic devices that can be rapidly fabricated using the Voxel8 3D printer. Voxel8 Inc. was incorporated in 2013 and is based in Somerville, Massachusetts.
Agrivida, Inc. is an agricultural biotechnology company that specializes in developing feed additives and renewable biomass-based alternative fuels. Founded in 2002 and based in Cambridge, Massachusetts, Agrivida focuses on nutritional solutions for a variety of livestock, including poultry, swine, dairy and beef cattle, and aquaculture. The company offers products such as GRAINZYME, a phytase feed additive for poultry, and INzyme Enzymes, which provide regulated enzymes for various applications including detergents and food production. In addition, Agrivida develops corn varieties optimized for producing ethanol from corn stover, contributing to the production of clean-burning, renewable fuels.
Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and will eventually be valuable for clinical diagnostic use.
It was founded in 2015 and headquartered in Cambridge, Massachusetts.
Verve Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to reduce the risk of coronary artery disease, a leading cause of death globally. Founded in 2018 and headquartered in Cambridge, Massachusetts, with a research facility in Philadelphia, the company leverages human genetic analysis and gene-editing technologies to create treatments that offer lifelong protection from this condition. Verve has established strategic alliances, including collaborations with Beam Therapeutics to advance delivery technologies targeting cardiovascular issues and with Verily for developing gene editing delivery vehicles. Formerly known as Endcadia, Verve Therapeutics rebranded in September 2019 to reflect its commitment to addressing heart disease through advanced genetic solutions.
Karuna Pharmaceuticals, Inc. engages in development of drugs for the treatment of schizophrenia. The company was incorporated in 2009 and is based in Boston, Massachusetts.
Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines for serious diseases. It utilizes its proprietary base editing technology, which allows for targeted modifications at the single base level in the genome without causing double-stranded breaks in DNA. Beam's therapeutic pipeline includes treatments for sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder 1A, and various ocular and central nervous system disorders. The company aims to provide long-lasting cures through its innovative approaches, which include gene correction, gene modification, gene activation, gene silencing, and multiplex editing. Beam Therapeutics was founded in 2017 and is committed to advancing the field of genetic medicine through research and clinical collaborations, including a partnership with Magenta Therapeutics.
Glympse Bio, Inc. is focused on developing modular nanoparticle sensors for diagnostics in fibrosis, cancer, immunology, and infectious diseases, as well as for monitoring drug response. The company utilizes engineered diagnostic agents that assess disease states within the body and convey this information to urine for analysis. Its flagship product, Glympse Inside, serves as a pan-disease engine intended to enhance disease monitoring and treatment response. Founded in 2015 and based in Cambridge, Massachusetts, Glympse Bio's innovative platform technology originated at MIT and is backed by a team of experts in nanomedicine and biomedical engineering.
KSQ Therapeutics is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by our proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a unique and more comprehensive understanding of disease biology. The quality of these insights enables their scientists to rapidly identify and validate high-confidence, patient-tailored, novel drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.
Karuna Pharmaceuticals, Inc. engages in development of drugs for the treatment of schizophrenia. The company was incorporated in 2009 and is based in Boston, Massachusetts.
Cytrellis Biosystems is a clinical stage medical technology company that designs and develops medical device for dermatology, scar reduction, and aesthetic medicine. Its devices are designed to remove sagging skin associated with aging without surgery or scarring, providing aesthetic practitioners an unprecedented ability to improve age related changes in skin.
Cytrellis Biosystems was founded in 2011 and is based in Boston, Massachusetts.
Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines for serious diseases. It utilizes its proprietary base editing technology, which allows for targeted modifications at the single base level in the genome without causing double-stranded breaks in DNA. Beam's therapeutic pipeline includes treatments for sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder 1A, and various ocular and central nervous system disorders. The company aims to provide long-lasting cures through its innovative approaches, which include gene correction, gene modification, gene activation, gene silencing, and multiplex editing. Beam Therapeutics was founded in 2017 and is committed to advancing the field of genetic medicine through research and clinical collaborations, including a partnership with Magenta Therapeutics.
Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and will eventually be valuable for clinical diagnostic use.
It was founded in 2015 and headquartered in Cambridge, Massachusetts.
Scholar Rock is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapies targeting growth factor signaling in serious diseases. The company’s lead product candidate, SRK-015, is a selective inhibitor of myostatin activation and is currently undergoing Phase II clinical trials for spinal muscular atrophy. Additionally, Scholar Rock is advancing SRK-181, which is in Phase I trials for treating cancers resistant to checkpoint inhibitors. The company employs a proprietary platform to design monoclonal antibodies that selectively modulate the activation of growth factors in disease microenvironments, addressing challenges associated with traditional growth factor inhibition. Scholar Rock is also developing a pipeline of candidates for a variety of conditions, including neuromuscular disorders, cancer, fibrosis, and anemia. Furthermore, the company has a collaboration with Gilead Sciences to explore specific inhibitors of transforming growth factor beta for fibrotic diseases. Founded in 2012, Scholar Rock aims to improve patient outcomes through its targeted therapeutic approach.
ImmusanT, Inc., a biotechnology company, develops therapies and personalized diagnostics to treat patients with celiac disease. The company focusses on disease-modifying approach to induce immune tolerance in autoimmune diseases. It offers Nexvax2, a therapeutic vaccine for celiac disease; and a diagnostic and monitoring tool to improve celiac disease management. ImmusanT, Inc. was founded in 2010 and is based in Cambridge, Massachusetts.
KSQ Therapeutics is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by our proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a unique and more comprehensive understanding of disease biology. The quality of these insights enables their scientists to rapidly identify and validate high-confidence, patient-tailored, novel drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.
Arbor Biotechnologies operator of a bio-discovery company intended to provide human diagnostic development service. The company's platform employs a diverse set of technologies and techniques including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening, enabling drug developers to accelerate the discovery of proteins for improving human health and sustainability.
Agrivida, Inc. is an agricultural biotechnology company that specializes in developing feed additives and renewable biomass-based alternative fuels. Founded in 2002 and based in Cambridge, Massachusetts, Agrivida focuses on nutritional solutions for a variety of livestock, including poultry, swine, dairy and beef cattle, and aquaculture. The company offers products such as GRAINZYME, a phytase feed additive for poultry, and INzyme Enzymes, which provide regulated enzymes for various applications including detergents and food production. In addition, Agrivida develops corn varieties optimized for producing ethanol from corn stover, contributing to the production of clean-burning, renewable fuels.
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company’s various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 1/2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.
Quanterix Corporation specializes in single-molecule analysis, offering a platform that significantly enhances sensitivity, precision, and robustness in clinical diagnostics, drug development, and life science research. Their technology enables rapid quantification and analysis of individual proteins and small molecules within complex biological samples, addressing various unmet medical needs. The ultra-sensitive detection solution, Simoa, allows researchers to closely examine biomarkers' roles in health and disease, facilitating earlier disease detection, improved prognosis, and more precise treatment methods. Founded in 2007, Quanterix is supported by prominent life science investors, aiming to improve the quality of life and longevity for future generations through advanced diagnostic capabilities.
Scholar Rock is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapies targeting growth factor signaling in serious diseases. The company’s lead product candidate, SRK-015, is a selective inhibitor of myostatin activation and is currently undergoing Phase II clinical trials for spinal muscular atrophy. Additionally, Scholar Rock is advancing SRK-181, which is in Phase I trials for treating cancers resistant to checkpoint inhibitors. The company employs a proprietary platform to design monoclonal antibodies that selectively modulate the activation of growth factors in disease microenvironments, addressing challenges associated with traditional growth factor inhibition. Scholar Rock is also developing a pipeline of candidates for a variety of conditions, including neuromuscular disorders, cancer, fibrosis, and anemia. Furthermore, the company has a collaboration with Gilead Sciences to explore specific inhibitors of transforming growth factor beta for fibrotic diseases. Founded in 2012, Scholar Rock aims to improve patient outcomes through its targeted therapeutic approach.
Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and will eventually be valuable for clinical diagnostic use.
It was founded in 2015 and headquartered in Cambridge, Massachusetts.
Agrivida, Inc. is an agricultural biotechnology company that specializes in developing feed additives and renewable biomass-based alternative fuels. Founded in 2002 and based in Cambridge, Massachusetts, Agrivida focuses on nutritional solutions for a variety of livestock, including poultry, swine, dairy and beef cattle, and aquaculture. The company offers products such as GRAINZYME, a phytase feed additive for poultry, and INzyme Enzymes, which provide regulated enzymes for various applications including detergents and food production. In addition, Agrivida develops corn varieties optimized for producing ethanol from corn stover, contributing to the production of clean-burning, renewable fuels.
Voxel8 Inc. designs and manufactures electronic devices. It offers desktop 3D printers that are used to print thermoplastics or UV resins. The company also provides Project Wire, a cloud software tool that is used for designing 3D printable electronic devices that can be rapidly fabricated using the Voxel8 3D printer. Voxel8 Inc. was incorporated in 2013 and is based in Somerville, Massachusetts.
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies for the treatment, prevention, and transmission control of infectious and progressive respiratory diseases. It offers inhaled cationic airway lining modulator drugs, which stimulate host defense mechanisms within the airway to treat and prevent influenza, rhinovirus, and chronic pulmonary diseases. The company was founded in 2003 and is based in Lexington, Massachusetts.
Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, aiming to provide alternatives to insulin injections. The company emerged from research by Professor Douglas Melton, which led to the discovery of a method for generating billions of functional, insulin-producing beta cells in the laboratory. This breakthrough technology has been exclusively licensed to Semma Therapeutics, which is now dedicated to creating a cell-based therapy that combines these proprietary cells with advanced devices to effectively replace the missing beta cells in diabetic patients without the need for immunosuppression. Established in 2014 and headquartered in Cambridge, Massachusetts, Semma Therapeutics operates as a subsidiary of Vertex Pharmaceuticals and is committed to bringing its novel therapeutic solutions to clinical settings, ultimately enhancing the quality of life for individuals living with diabetes.
Chiasma (Israel) ltd., is a biopharmaceutical company which develops oral drugs based on transient permeability enhancer system. The company offers oral octreotide acetate for the treatment of acromegaly. Its pipeline products include novel drugs which addresses unmet needs for well-defined markets. The company focuses primarily on orphan indications. The company was founded in 2001 and is based in Ness Ziona, Israel. Chiasma (Israel) ltd. operates as a subsidiary of Chiasma, Inc.
Cytrellis Biosystems is a clinical stage medical technology company that designs and develops medical device for dermatology, scar reduction, and aesthetic medicine. Its devices are designed to remove sagging skin associated with aging without surgery or scarring, providing aesthetic practitioners an unprecedented ability to improve age related changes in skin.
Cytrellis Biosystems was founded in 2011 and is based in Boston, Massachusetts.
Syros Pharmaceuticals is a biopharmaceutical company dedicated to developing treatments for cancer and genetic disorders through innovative gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently undergoing a Phase II clinical trial for specific patient subsets with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor in a Phase I clinical trial for select advanced solid tumors. Syros employs a unique approach that integrates gene regulatory circuit mapping and modulation of gene expression factors, supported by a proprietary platform of assay technologies and bioinformatics. The company collaborates with Incyte Corporation to discover therapeutic targets, particularly for myeloproliferative neoplasms, and has a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. Founded in 2011 and headquartered in Cambridge, Massachusetts, Syros Pharmaceuticals was previously known as LS22, Inc. and rebranded in 2012.
Scholar Rock is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapies targeting growth factor signaling in serious diseases. The company’s lead product candidate, SRK-015, is a selective inhibitor of myostatin activation and is currently undergoing Phase II clinical trials for spinal muscular atrophy. Additionally, Scholar Rock is advancing SRK-181, which is in Phase I trials for treating cancers resistant to checkpoint inhibitors. The company employs a proprietary platform to design monoclonal antibodies that selectively modulate the activation of growth factors in disease microenvironments, addressing challenges associated with traditional growth factor inhibition. Scholar Rock is also developing a pipeline of candidates for a variety of conditions, including neuromuscular disorders, cancer, fibrosis, and anemia. Furthermore, the company has a collaboration with Gilead Sciences to explore specific inhibitors of transforming growth factor beta for fibrotic diseases. Founded in 2012, Scholar Rock aims to improve patient outcomes through its targeted therapeutic approach.
SAGE Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative treatments for central nervous system (CNS) disorders. Its lead product, ZULRESSO, is an intravenous formulation of brexanolone designed for postpartum depression. The company's pipeline includes SAGE-217, a neuroactive steroid in Phase III trials for various depressive disorders and anxiety, and SAGE-324, currently in Phase II trials for essential tremors and previously tested for other neurological conditions. Additionally, SAGE-718, which targets multiple CNS disorders, has completed Phase I trials, while SAGE-904 and SAGE-689 are in early clinical stages for NMDA-related disorders. SAGE Therapeutics has formed strategic collaborations with Shionogi & Co., Ltd. and Biogen Inc. for the development and commercialization of its key product candidates. Founded in 2010 and headquartered in Cambridge, Massachusetts, the company aims to address the unmet needs of patients affected by debilitating CNS disorders through scientific innovation and strategic partnerships.
WuXi NextCODE is a clinical diagnostics company focused on genomics, providing a platform that helps physicians derive clinical insights for rapid patient diagnoses. The company specializes in genome interpretation, data analysis, and data mining services, alongside offering security and data protection solutions. It also provides custom integration services and both clinical-grade and non-clinical-grade sequencing services. Originating from technology developed at deCODE genetics, WuXi NextCODE aims to facilitate the integration of genomic data into patient care. Based in Cambridge, Massachusetts, the company became a subsidiary of WuXi PharmaTech in 2015 and was rebranded as Genuity Science in 2020.
SAGE Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative treatments for central nervous system (CNS) disorders. Its lead product, ZULRESSO, is an intravenous formulation of brexanolone designed for postpartum depression. The company's pipeline includes SAGE-217, a neuroactive steroid in Phase III trials for various depressive disorders and anxiety, and SAGE-324, currently in Phase II trials for essential tremors and previously tested for other neurological conditions. Additionally, SAGE-718, which targets multiple CNS disorders, has completed Phase I trials, while SAGE-904 and SAGE-689 are in early clinical stages for NMDA-related disorders. SAGE Therapeutics has formed strategic collaborations with Shionogi & Co., Ltd. and Biogen Inc. for the development and commercialization of its key product candidates. Founded in 2010 and headquartered in Cambridge, Massachusetts, the company aims to address the unmet needs of patients affected by debilitating CNS disorders through scientific innovation and strategic partnerships.
Syros Pharmaceuticals is a biopharmaceutical company dedicated to developing treatments for cancer and genetic disorders through innovative gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently undergoing a Phase II clinical trial for specific patient subsets with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor in a Phase I clinical trial for select advanced solid tumors. Syros employs a unique approach that integrates gene regulatory circuit mapping and modulation of gene expression factors, supported by a proprietary platform of assay technologies and bioinformatics. The company collaborates with Incyte Corporation to discover therapeutic targets, particularly for myeloproliferative neoplasms, and has a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. Founded in 2011 and headquartered in Cambridge, Massachusetts, Syros Pharmaceuticals was previously known as LS22, Inc. and rebranded in 2012.
Quanterix Corporation specializes in single-molecule analysis, offering a platform that significantly enhances sensitivity, precision, and robustness in clinical diagnostics, drug development, and life science research. Their technology enables rapid quantification and analysis of individual proteins and small molecules within complex biological samples, addressing various unmet medical needs. The ultra-sensitive detection solution, Simoa, allows researchers to closely examine biomarkers' roles in health and disease, facilitating earlier disease detection, improved prognosis, and more precise treatment methods. Founded in 2007, Quanterix is supported by prominent life science investors, aiming to improve the quality of life and longevity for future generations through advanced diagnostic capabilities.
Bluebird Bio is a clinical-stage biotechnology company focused on developing transformative gene therapies for severe genetic diseases and cancer. The company is engaged in researching and commercializing therapies that aim to genetically modify patients' cells to correct the underlying genetic causes of diseases. Key programs include LentiGlobin for β-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy. In oncology, bluebird bio is developing CAR T cell therapies, such as bb2121 and bb21217, for multiple myeloma. The company has formed strategic collaborations with Bristol-Myers Squibb and Regeneron Pharmaceuticals to advance gene therapies in oncology, and works with various partners to develop innovative solutions in cancer treatment and in vivo genome editing for genetic disorders. Founded in 1992 and headquartered in Cambridge, Massachusetts, bluebird bio generates revenue through collaboration arrangements, research fees, license fees, and grants.
Chiasma (Israel) ltd., is a biopharmaceutical company which develops oral drugs based on transient permeability enhancer system. The company offers oral octreotide acetate for the treatment of acromegaly. Its pipeline products include novel drugs which addresses unmet needs for well-defined markets. The company focuses primarily on orphan indications. The company was founded in 2001 and is based in Ness Ziona, Israel. Chiasma (Israel) ltd. operates as a subsidiary of Chiasma, Inc.
Permeon Biologics is focused on improving human health through its innovative Intraphilin Technology Platform. This platform identifies naturally occurring human proteins known for their ability to enhance cellular uptake and permeate cell membranes effectively. By leveraging these "supercharged proteins," Permeon Biologics aims to develop a new generation of therapeutic drugs that can deliver functional proteins capable of replacing or restoring defective cellular pathways associated with various diseases. This approach represents a significant advancement in the field of intracellular biologics, positioning the company at the forefront of therapeutic innovation.
Agios Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of therapies targeting cellular metabolism, particularly in cancer and rare genetic disorders. The company offers TIBSOVO, an oral targeted inhibitor approved for treating relapsed or refractory acute myeloid leukemia (AML) and newly diagnosed AML, as well as IDHIFA, which targets AML patients with specific genetic mutations. Agios is advancing multiple clinical programs, including TIBSOVO for frontline AML and cholangiocarcinoma, and developing mitapivat for pyruvate kinase deficiency and thalassemia. Other investigational compounds include vorasidenib for solid tumors and AG-270 for specific cancer types. Agios employs a precision medicine approach, focusing on genetically or biomarker-defined patient populations to enhance the potential for successful early clinical proof of concept and accelerated approvals. The company was originally established in 2007 under the name Cancer Metabolism Therapeutics before rebranding to Agios Pharmaceuticals in 2008.
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies for the treatment, prevention, and transmission control of infectious and progressive respiratory diseases. It offers inhaled cationic airway lining modulator drugs, which stimulate host defense mechanisms within the airway to treat and prevent influenza, rhinovirus, and chronic pulmonary diseases. The company was founded in 2003 and is based in Lexington, Massachusetts.
Bluebird Bio is a clinical-stage biotechnology company focused on developing transformative gene therapies for severe genetic diseases and cancer. The company is engaged in researching and commercializing therapies that aim to genetically modify patients' cells to correct the underlying genetic causes of diseases. Key programs include LentiGlobin for β-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy. In oncology, bluebird bio is developing CAR T cell therapies, such as bb2121 and bb21217, for multiple myeloma. The company has formed strategic collaborations with Bristol-Myers Squibb and Regeneron Pharmaceuticals to advance gene therapies in oncology, and works with various partners to develop innovative solutions in cancer treatment and in vivo genome editing for genetic disorders. Founded in 1992 and headquartered in Cambridge, Massachusetts, bluebird bio generates revenue through collaboration arrangements, research fees, license fees, and grants.
They are a clinical-stage nanomedicine platform company developing Accurins™, our novel targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Our strategy is to leverage our medicinal nanoengineering platform to develop our own pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and metastatic castrate-resistant prostate cancer (mCRPC). To date in 2013, we have announced collaborations with Amgen, Pfizer and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines.
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies for the treatment, prevention, and transmission control of infectious and progressive respiratory diseases. It offers inhaled cationic airway lining modulator drugs, which stimulate host defense mechanisms within the airway to treat and prevent influenza, rhinovirus, and chronic pulmonary diseases. The company was founded in 2003 and is based in Lexington, Massachusetts.
Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.
Surface Logix is a drug development company which uses its expertise in biophysical chemistry to create new small molecule drugs with significantly improved pharmacokinetic (PK) and pharmacodynamic (PD) properties compared with class leaders.
Quanterix Corporation specializes in single-molecule analysis, offering a platform that significantly enhances sensitivity, precision, and robustness in clinical diagnostics, drug development, and life science research. Their technology enables rapid quantification and analysis of individual proteins and small molecules within complex biological samples, addressing various unmet medical needs. The ultra-sensitive detection solution, Simoa, allows researchers to closely examine biomarkers' roles in health and disease, facilitating earlier disease detection, improved prognosis, and more precise treatment methods. Founded in 2007, Quanterix is supported by prominent life science investors, aiming to improve the quality of life and longevity for future generations through advanced diagnostic capabilities.
Agios Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of therapies targeting cellular metabolism, particularly in cancer and rare genetic disorders. The company offers TIBSOVO, an oral targeted inhibitor approved for treating relapsed or refractory acute myeloid leukemia (AML) and newly diagnosed AML, as well as IDHIFA, which targets AML patients with specific genetic mutations. Agios is advancing multiple clinical programs, including TIBSOVO for frontline AML and cholangiocarcinoma, and developing mitapivat for pyruvate kinase deficiency and thalassemia. Other investigational compounds include vorasidenib for solid tumors and AG-270 for specific cancer types. Agios employs a precision medicine approach, focusing on genetically or biomarker-defined patient populations to enhance the potential for successful early clinical proof of concept and accelerated approvals. The company was originally established in 2007 under the name Cancer Metabolism Therapeutics before rebranding to Agios Pharmaceuticals in 2008.
They are a clinical-stage nanomedicine platform company developing Accurins™, our novel targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Our strategy is to leverage our medicinal nanoengineering platform to develop our own pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and metastatic castrate-resistant prostate cancer (mCRPC). To date in 2013, we have announced collaborations with Amgen, Pfizer and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines.
Ensemble Discovery is developing a new class of therapeutics - the Ensemblinsâ„¢, orally bioavailable small molecule macrocyclic compounds that have the potential to behave like biologics and can disrupt protein-protein interactions. They have two complementary platforms that provide access to these molecules. Firstly, they use their proprietary DNA-Programmed Chemistryâ„¢ (DPCâ„¢) platform to generate hundreds of thousands of these molecules for rapid screening. Secondly, they have highly developed methods for the synthesis of Ensemblins as discrete molecules using conventional chemistry.
Surface Logix is a drug development company which uses its expertise in biophysical chemistry to create new small molecule drugs with significantly improved pharmacokinetic (PK) and pharmacodynamic (PD) properties compared with class leaders.
Ahura Scientific Inc. specializes in the development of rugged, ultra-compact optical systems designed for the immediate identification and authentication of both liquid and solid chemical substances. The company serves a diverse clientele, including agencies and organizations in the homeland security, life sciences, industrial, and medical sectors. With a commitment to quality, Ahura Scientific manufactures its products in the United States at an ISO 9001-certified facility, ensuring exceptional portability and high performance in the field.
Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.
Chiasma (Israel) ltd., is a biopharmaceutical company which develops oral drugs based on transient permeability enhancer system. The company offers oral octreotide acetate for the treatment of acromegaly. Its pipeline products include novel drugs which addresses unmet needs for well-defined markets. The company focuses primarily on orphan indications. The company was founded in 2001 and is based in Ness Ziona, Israel. Chiasma (Israel) ltd. operates as a subsidiary of Chiasma, Inc.
Magen BioSciences is a Biotechnology company located in 100 Beaver Street, Suite 101, Waltham, MA, United States.
AmberWave, Inc., formerly AmberWave Systems Corporation, engages in the research, development, and licensing of technologies for semiconductor manufacturing. It provides Strained Silicon, a technology that is used in microchips to improve performance and decrease power consumption; and Aspect Ratio Trapping, a technology, which is used to make chips for silicon-based photonics and photovoltaic cells. The company was founded in 1998 and is headquartered in Salem, New Hampshire. AmberWave Systems Corporation is a former subsidiary of U.S. Robotics Corp.
Surface Logix is a drug development company which uses its expertise in biophysical chemistry to create new small molecule drugs with significantly improved pharmacokinetic (PK) and pharmacodynamic (PD) properties compared with class leaders.
Ahura Scientific Inc. specializes in the development of rugged, ultra-compact optical systems designed for the immediate identification and authentication of both liquid and solid chemical substances. The company serves a diverse clientele, including agencies and organizations in the homeland security, life sciences, industrial, and medical sectors. With a commitment to quality, Ahura Scientific manufactures its products in the United States at an ISO 9001-certified facility, ensuring exceptional portability and high performance in the field.
AmberWave, Inc., formerly AmberWave Systems Corporation, engages in the research, development, and licensing of technologies for semiconductor manufacturing. It provides Strained Silicon, a technology that is used in microchips to improve performance and decrease power consumption; and Aspect Ratio Trapping, a technology, which is used to make chips for silicon-based photonics and photovoltaic cells. The company was founded in 1998 and is headquartered in Salem, New Hampshire. AmberWave Systems Corporation is a former subsidiary of U.S. Robotics Corp.
Ensemble Discovery is developing a new class of therapeutics - the Ensemblinsâ„¢, orally bioavailable small molecule macrocyclic compounds that have the potential to behave like biologics and can disrupt protein-protein interactions. They have two complementary platforms that provide access to these molecules. Firstly, they use their proprietary DNA-Programmed Chemistryâ„¢ (DPCâ„¢) platform to generate hundreds of thousands of these molecules for rapid screening. Secondly, they have highly developed methods for the synthesis of Ensemblins as discrete molecules using conventional chemistry.
Ensemble Therapeutics Corporation is engaged in the discovery and development of small molecule therapies aimed at treating cancer and other serious diseases. The company focuses on immuno-oncology programs, including the development of therapies targeting Indoleamine 2, 3-dioxygenase 1 (IDO-1), a protein that plays a role in tumor immune evasion. Additionally, Ensemble Therapeutics is involved in programs related to the ubiquitin-proteasome system, specifically targeting Ubiquitin-specific protease 9x, which is linked to the survival of aggressive tumors such as melanoma and glioblastoma. The company also develops inhibitors of apoptosis proteins, which prevent tumor cell death, and Cyclophilins, which facilitate protein folding. Founded in 2002 and based in Cambridge, Massachusetts, Ensemble Therapeutics aims to offer innovative treatments by addressing previously inaccessible drug targets, thereby providing patients with safe and effective therapeutic options.
As of December 2007, Reef Point Systems, Inc. was acquired by NextPoint Networks, Inc. Reef Point Systems, Inc. provides security solutions for converged wireless and wireline networks in the United States. Its iQ product portfolio enables fixed/mobile convergence security, secure mobile access, network infrastructure protection, and managed security services. It enables operators to secure voice over the Internet protocol, Internet protocol television, and voice, video, and data services from a converged Internet protocol infrastructure. The company’s iQ family lets wireless service providers protect the wireless network infrastructure and deliver multimedia services for mobile users over unlicensed mobile access and Internet protocol multimedia subsystem infrastructure. Its products also enable service providers to offer various security services, including virtual private networks, firewalls, denial of service attack prevention, content filtering, and remote access. The company, formerly known as Quarry Technologies, Inc., was founded in 1998 and is headquartered in Burlington, Massachusetts.
Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.
Alnylam Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. The company focuses on addressing various medical conditions, including genetic diseases, cardio-metabolic disorders, hepatic infectious diseases, and central nervous system and ocular diseases. Its marketed products include ONPATTRO, which treats polyneuropathy associated with hereditary transthyretin-mediated amyloidosis, and GIVLAARI, aimed at adults with acute hepatic porphyria. Alnylam's pipeline includes investigational therapies such as givosiran for acute hepatic porphyria, lumasiran for primary hyperoxaluria type 1, patisiran for transthyretin amyloidosis with cardiomyopathy, and vutrisiran for transthyretin amyloidosis. The company fosters strategic alliances with organizations like Sanofi Genzyme and Ionis Pharmaceuticals, and collaborates with Vir Biotechnology to advance RNAi therapeutics for coronavirus infections. Founded in 2002, Alnylam Pharmaceuticals is headquartered in Cambridge, Massachusetts.
Surface Logix is a drug development company which uses its expertise in biophysical chemistry to create new small molecule drugs with significantly improved pharmacokinetic (PK) and pharmacodynamic (PD) properties compared with class leaders.
Ahura Scientific Inc. specializes in the development of rugged, ultra-compact optical systems designed for the immediate identification and authentication of both liquid and solid chemical substances. The company serves a diverse clientele, including agencies and organizations in the homeland security, life sciences, industrial, and medical sectors. With a commitment to quality, Ahura Scientific manufactures its products in the United States at an ISO 9001-certified facility, ensuring exceptional portability and high performance in the field.
AmberWave, Inc., formerly AmberWave Systems Corporation, engages in the research, development, and licensing of technologies for semiconductor manufacturing. It provides Strained Silicon, a technology that is used in microchips to improve performance and decrease power consumption; and Aspect Ratio Trapping, a technology, which is used to make chips for silicon-based photonics and photovoltaic cells. The company was founded in 1998 and is headquartered in Salem, New Hampshire. AmberWave Systems Corporation is a former subsidiary of U.S. Robotics Corp.
AmberWave, Inc., formerly AmberWave Systems Corporation, engages in the research, development, and licensing of technologies for semiconductor manufacturing. It provides Strained Silicon, a technology that is used in microchips to improve performance and decrease power consumption; and Aspect Ratio Trapping, a technology, which is used to make chips for silicon-based photonics and photovoltaic cells. The company was founded in 1998 and is headquartered in Salem, New Hampshire. AmberWave Systems Corporation is a former subsidiary of U.S. Robotics Corp.
As of December 2007, Reef Point Systems, Inc. was acquired by NextPoint Networks, Inc. Reef Point Systems, Inc. provides security solutions for converged wireless and wireline networks in the United States. Its iQ product portfolio enables fixed/mobile convergence security, secure mobile access, network infrastructure protection, and managed security services. It enables operators to secure voice over the Internet protocol, Internet protocol television, and voice, video, and data services from a converged Internet protocol infrastructure. The company’s iQ family lets wireless service providers protect the wireless network infrastructure and deliver multimedia services for mobile users over unlicensed mobile access and Internet protocol multimedia subsystem infrastructure. Its products also enable service providers to offer various security services, including virtual private networks, firewalls, denial of service attack prevention, content filtering, and remote access. The company, formerly known as Quarry Technologies, Inc., was founded in 1998 and is headquartered in Burlington, Massachusetts.